MoonLake Immunotherapeutics
NASDAQ:MLTX
Overview | Financials
Company Name | MoonLake Immunotherapeutics |
Symbol | MLTX |
Currency | USD |
Price | 50.67 |
Market Cap | 3,186,565,362 |
Dividend Yield | 0% |
52-week-range | 35.53 - 64.98 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jorge Santos da Silva |
Website | https://www.moonlaketx.com |
An error occurred while fetching data.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD